Atlas
Market PulseSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › LUPIN

LUPIN

Lupin Limited
Mid-capPharma ↗

What the six lenses say about LUPIN — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹2503.3
2026-07-10
VWAP · 1Y anchor
₹2140
+17.0% from VWAP
P/E · TTM
21.4×
TTM EPS ₹116.7
52-week range
100%
position low→high
RSI(14)
70
momentum

Own sector index

Pharma ↗
Overweight

1M

+6.2%

3M

+15.8%

1Y

+16.2%

Breadth >EMA21

72%

How LUPIN’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
8.0
avg conviction decile
Leadership
1/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Mid-cap cohortDRaw
TechnicalD10100›

The actual numbers

Price vs VWAP (1y)+17.0%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+12.9%
Price vs 50-EMA+6.7%
RSI(14)70
RS vs Nifty 500 · 3M+4.0%
RS vs sector · 3M-8.5%
52-week range100%
Volume vs 30d avg0.65×
Volume vs 60d avg0.52×
ATR(14) · volatility56.5
Bollinger width · vol contraction0.123
FundamentalD1087›

The actual numbers

Return on equity (ROE)29.1%
Return on capital (ROCE)30.3%
Operating margin26.1%
Net margin19.2%
Revenue growth · YoY+23.1%
EPS growth · YoY+62.2%
Debt / equity0.29×

Full 8-quarter history in the financials table below.

ValuationD735›

The actual numbers

P/E (TTM)21.4×
TTM EPS₹116.7
52-week range100%
CatalystD1077›

The actual numbers

Earnings & momentum173
Capital actions23
Governance117

Every filing in the corporate-announcements panel below.

FlowD650›

The actual numbers

Promoter holding46.9%
Delivery · 30d avg53.9%
Up/down-day asymmetry-1.3pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Mid-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D10 + D6 ) ÷ 2 = 8.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
95
Conviction score 95/100 · avg-decile strength 8.0/10
Conviction score95/100›
TechnicalD10›
FundamentalD10›
ValuationD7›
CatalystD10›
FlowD6›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+1.5pp
+5.2pp
+8.2pp
+7.6pp
+21.4pp
+37.6pp
Nifty 500
Broad-market baseline
+1.0pp
+5.1pp
+7.6pp
+4.0pp
+16.4pp
+33.8pp
Sector
Own-sector index
—
—
+5.2pp
-8.5pp
+2.0pp
+15.9pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

LUPIN daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
2503.30+44.30

Relative strength

RS vs baseline · rebased to 100

LUPIN ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
136.41+1.40

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)5,6005,6735,7685,6676,2687,0487,1687,475
↳ change QoQ—+1.3%+1.7%-1.7%+10.6%+12.4%+1.7%+4.3%
EBITDA (₹cr)1,3091,3831,4101,3211,7272,3412,2622,486
EBITDA margin23.4%24.4%24.4%23.3%27.6%33.2%31.6%33.3%
PAT (₹cr)8068598597821,2211,4851,1811,469
↳ change QoQ—+6.7%-0.1%-8.9%+56.1%+21.6%-20.5%+24.4%
Net margin14.4%15.2%14.9%13.8%19.5%21.1%16.5%19.7%
EPS (₹)17.5818.7018.7516.9226.6932.3625.7331.94
D/E————————
YoY growth · Mar '26Revenue +31.9% YoYPAT +87.9% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 17 Jun '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 8 Jun '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 4 Jun '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 3 Jun '26
    LOWgovernance
    ESOP/ESOS/ESPS
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 3 Jun '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 29 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 29 May '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 28 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 28 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 25 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 19 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 18 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 15 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 14 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds LUPIN

Mutual funds holding LUPIN (10)

FundWeightAUM ₹crGrade
HDFC Flexi Cap Gr0.74%1,01,822
Nippon India Multi Cap Bns1.12%54,585
Nippon India Multi Cap Gr1.12%54,585
Nippon India Multi Cap Dir Bns1.12%54,585
Nippon India Large Cap Bns1.07%53,227
Nippon India Large Cap Dir Bns1.07%53,227
Nippon India Large Cap Instl Bns1.07%53,227
Nippon India Large Cap Gr1.07%53,227
Nippon India Growth Mid Cap Dir Bns1.08%49,169
Nippon India Growth Md Cp Reg Gr PlGrOpt1.08%49,169

ETFs holding LUPIN (10)

ETFWeightGrade
Nippon India Nifty Pharma ETF6.35%
ICICI Pru Nifty Healthcare ETF5.40%
Aditya BSL Nifty Healthcare ETF5.30%
DSP Nifty Healthcare ETF5.30%
Axis NIFTY Healthcare ETF5.30%
Mirae Asset Nifty 500 Healthcare ETF4.36%
Motilal Oswal BSE Healthcare ETF3.74%
Kotak Nifty Midcap 50 ETF2.62%
SBI S&P BSE Sensex Next 50 ETF2.10%
UTI BSE Sensex Next 50 ETF2.10%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma